Free shipping on all orders over $ 500

OC000459

Cat. No. M2091

All AbMole products are for research use only, cannot be used for human consumption.

OC000459 Structure
Synonym:

Timapiprant

Size Price Availability Quantity
5mg USD 60 In stock
10mg USD 95 In stock
25mg USD 190 In stock
50mg USD 300 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

OC000459 is a potent, selective, and orally active D prostanoid receptor 2 antagonist that inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophils. OC000459 inhibited chemotaxis (IC50 = 0.028 μM) of human Th2 lymphocytes and cytokine production (IC50 = 0.019 μM) by human Th2 lymphocytes. OC000459 also inhibited the activation of Th2 cells and eosinophils in response to supernatants from IgE/anti-IgE-activated human mast cells. OC000459 was shown to inhibit blood eosinophilia in rats induced by 13,14-dihydro-15-keto PGD2 (Item No. 12610) (ED50 = 0.04 mg/kg) and airway eosinophilia in guinea pigs in response to an aerosol of 13,14-dihydro-15-keto PGD2 (ED50 = 0.01 mg/kg). OC000459 treatment inhibited LAR and post-allergen increase in sputum eosinophils and led to a significant and persistent reduction in the symptoms of rhinoconjunctivitis.

Chemical Information
Molecular Weight 348.37
Formula C21H17FN2O2
CAS Number 851723-84-7
Solubility (25°C) DMSO 4 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Horak F, et al. Allergy. The CRTH2 antagonist OC000459 reduces nasal and ocular symptoms in allergic subjects exposed to grass pollen, a randomised, placebo-controlled, double-blind trial.

[2] Singh D, et al. Eur Respir J. Inhibition of the asthmatic allergen challenge response by the CRTH2 antagonist OC000459.

[3] Pettipher R, et al. J Pharmacol Exp Ther. Pharmacologic profile of OC000459, a potent, selective, and orally active D prostanoid receptor 2 antagonist that inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophils.

[4] Barnes N, et al. Clin Exp Allergy. A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma.

Related GPR/FFAR Products
GW9508

GW9508 is a potent and selective G protein-coupled receptors FFA1 (GPR40) and GPR120 agonist with pEC50s of 7.32 and 5.46, respectively. GW9508 has anti-inflammatory and anti-atherosclerotic activities. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (KATP) channels opener.

Fasiglifam (TAK-875) Hemihydrate

Fasiglifam (TAK-875) Hemihydrate is a novel, orally available, selective GPR40 agonist.

AMG-837

AMG 837 is a potent, orally bioavailable GPR40 agonist with EC50 of 14 nM.

AZD1981

AZD1981 is a potent, selective CRTh2 (DP2) receptor antagonist with IC50 of 4 nM, showing >1000-fold selectivity over more than 340 other enzymes and receptors, including DP1.

GSK1292263

GSK1292263 is a novel GPR119 agonist, showing potential for the treatment of type 2 diabetes.

  Catalog
Abmole Inhibitor Catalog




Keywords: OC000459, Timapiprant supplier, GPR/FFAR, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.